Project Overview
CBD-BD is a clinical trial which aims to determine if cannabidiol (CBD) is helpful in improving symptoms of bipolar depression in comparison to placebo when added to participants’ current medications over a 6-week period. A significant portion of bipolar depressed patients do not respond to, or have difficulty tolerating, existing treatments, thus, the outcomes of this trial will contribute valuable insights to the development of novel and improved therapeutic options for people living with bipolar disorder. This double-blind, phase III, parallel group randomized controlled trial is led by Dr. Lakshmi Yatham at the Mood Disorders Centre in the UBC Department of Psychiatry, with sites across Canada.
“The FoM Digital Solutions Research Technology team have provided consistent, high-quality support to our CBD-BD project, having quickly created an intuitive yet highly functional database for our national study centres to use. Our research has benefited from a dynamic partnership with the Research Technology team, who offer updated tools to enhance data integrity and suggest thoughtful, proactive solutions. Their flexibility and willingness to adapt to our complex and unique needs, while maintaining a high standard of work and support, have been fundamental to the success of our project. We highly value our partnership with the Research Technology team, and look forward to working with them again on future projects.”
– Dr. Shannon Reid